Targeting mitochondrial metabolism with CPI-613 in chemoresistant ovarian tumors

Mary P Udumula[1,2], Faraz Rashid[3], Harshit Singh[1,2], Tim Pardee[4], Sanjeev Luther[5], Tanya

Bhardwaj[1,6], Km Anjaly[1,2], Sofia Piloni[1,2], Miriana Hijaz[1,2], Radhika Gogoi[7], Philip A Philip[2,8],

Adnan R Munkarah[1,2], Shailendra Giri[3] and Ramandeep Rattan[1,2,5]

[1]Department of Gynecologic Oncology, Henry Ford Hospital, 2779 West Grand Blvd., Detroit,

MI

[2]Henry Ford Cancer Institute, 2800 West Grand Blvd., Detroit, MI

[3]Department of Neurology, Henry Ford Hospital, 2779 West Grand Blvd., Detroit, MI

[4]Comprehensive Cancer Center of Atrium Health Wake Forest Baptist, Winston-Salem NC 27157

[5]Eterna Therapeutics 1035 Cambridge, MA 02141

[6]Department of Biology, University of Michigan, 204 Washtenaw Ave, Ann Arbor, MI 48109

[7]Department of Oncology, Wayne Sate School of Medicine and Karmanos Cancer Institute, 4100

John R St, Detroit, MI 48201

[8] Department of Hematology Oncology, Henry Ford Hospital, 2779 West Grand Blvd., Detroit,

MI

Corresponding Author: Ramandeep Rattan, Division of Gynecology Oncology, Department of

Women's Health Services, One Ford Place 5D45, Detroit, MI 48202; Telephone: (313) 876-

7381; Fax: 313-876-3415; Email: rrattan1@hfhs.org

Abstract

Background: There is evidence indicating that chemoresistance in tumor cells is mediated by the reconfiguration of the tricarboxylic acid cycle, leading to heightened mitochondrial activity and oxidative phosphorylation (OXPHOS). Previously, we have shown that ovarian cancer cells that are resistant to chemotherapy display increased OXPHOS, mitochondrial function, and metabolic flexibility. To exploit this weakness in chemoresistant ovarian cancer cells, we examined the effectiveness of the mitochondrial inhibitor CPI-613 in treating preclinical ovarian cancer.

Methods: Chemosensitive OVCAR3, and chemoresistant CAOV3 and F2 ovarian cancer cells lines and their xenografts in nude mice were used. Functional metabolic studies were performed using Seahorse instrument. Metabolite quantification was performed using LC/MS/MS.

Results: Mice treated with CPI-613 exhibited a notable increase in overall survival and a reduction in tumor development and burden in OVCAR3, F2, and CAOV3 xenografts. CPI-613 suppressed the activity of pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase complex, which are two of its targets. This led to a reduction in OXPHOS and tricarboxylic acid cycle activity in all 3 xenografts. The addition of CPI-613 enhanced the responsiveness of chemotherapy in the chemoresistant F2 and CAOV3 tumors, resulting in a notable improvement in survival rates and a reduction in tumor size as compared to using chemotherapy alone. CPI-613 reduced the chemotherapy-induced OXPHOS in chemoresistant tumors. The study revealed that the mechanism by which CPI-613 inhibits tumor growth is through mitochondrial collapse. This is evidenced by an increase in superoxide production within the mitochondria, a decrease in ATP generation, and the release of cytochrome C, which triggers mitochondria-induced apoptosis. Our study demonstrates the translational potential of CPI-613 against chemoresistant ovarian tumors.

Keywords: ovarian cancer, CPI-613, mitochondrial inhibition, apoptosis

Background

Ovarian cancer ranks as the eighth most common cancer among women globally and is the fifth

leading cause of cancer-related fatalities in women [1]. The treatment for ovarian cancer,

specifically high grade serous ovarian cancer, includes major cytoreductive surgery followed by

standard of care chemotherapy consisting of carboplatin and paclitaxel or neoadjuvant

chemotherapy followed by cytoreduction and additional chemotherapy, based upon the patient

status [2]. Approximately 75% of patients with advanced stage disease will recur, either with

refractory chemoresistant tumors or tumors that will eventually develop chemoresistance [2, 3].

Chemoresistance is a significant challenge in the treatment of ovarian cancer, necessitating the

development of innovative medicines to effectively counteract the aggressive growth of tumors

[3-5].

Reprogramming of the metabolism is now a well-established hallmark of cancers [6],
where dysregulated cellular energetics is a key feature of metabolic rewiring [7, 8]. Increasing data
shows that adapting to aerobic glycolysis in cancer cells does not remove the reliance on oxidative
phosphorylation (OXPHOS) [9, 10]. OXPHOS has been demonstrated to be the primary energy
source for various cancers, with active mitochondria playing a crucial role in several tumor
characteristics, including tumor growth, metastasis, recurrence, response and resistance to drugs
and preservation of cancer stem cells (CSCs) [11-16]. We have previously demonstrated that
ovarian cancer cell lines that are resistant to chemotherapy exhibit heightened metabolic activity,
displaying increased OXPHOS through an augmented tricarboxylic acid (TCA) cycle, when
compared to cell lines that are sensitive to chemotherapy [16]. We have also shown that when
sensitive cells are exposed to chemotherapy, they shift from using glycolysis to employing
OXPHOS, and this change is associated with their sensitivity [16]. These studies provide evidence

of the connection between chemoresistance and mitochondrial function. A promising new

approach to therapy are metabolic inhibitors, particularly those that target mitochondria [17].

We chose the mitochondrial inhibitor CPI-613 (devimistat) to investigate if inhibiting

mitochondrial function can alleviate chemoresistance in ovarian cancer models. CPI-613 is a

lipoic acid analog that blocks 2 crucial points in the TCA cycle: the pyruvate dehydrogenase

complex (PDHc), which facilitates the entry of pyruvate, and the alpha-ketoglutarate

dehydrogenase complex (αKGDC), which facilitates the incorporation of glutamine into the

TCA cycle [18-21]. Preclinical studies have shown the anti-tumor effect of CPI-613 in lung [22],

ovarian [20], pancreatic [21, 23, 24], head and neck [25], clear cell sarcoma [26] and colorectal

cancers [27], attributing the mechanism to be inhibition of both PDH and αKGDH, culminating

in the suppression of the TCA cycle and mitochondria. CPI-613 has undergone rigorous

evaluation in many clinical trials to assess its safety and effectiveness. Although the initial trials

of CPI-613 in combination with chemotherapy showed promise [19, 28-30], subsequent larger

trials in pancreatic cancer and acute myeloid leukemia failed to deliver the anticipated survival

benefits [31-33]. Nevertheless, subsequent analysis of clinical trials demonstrated a statistically

significant and beneficial rise in a specific group of patients when the modified FOLFIRINOX

regimen was combined with the treatment for pancreatic cancer and in older patients acute

myeloid leukemia [24, 33]. Therefore, CPI-613 retains promise, provided that its specific

suitability for certain populations and types of tumors has been determined.

In this study, we assess and illustrate the effectiveness of CPI-613 in preclinical models

of ovarian cancer that are sensitive and resistant to chemotherapy. Our findings indicate that

CPI-613 induces apoptosis in tumor cells via mitochondrial collapse. The research provides

compelling data for assessing the effectiveness of CPI-613 in ovarian cancer patients, namely

those who have demonstrated resistance to chemotherapy.

Methods

Cell lines and reagents

OVCAR3 is a human adenocarcinoma cell line used as a chemosensitive cell line and CAOV3,

F2 human epithelial ovarian cancer cells were used as a resistant model for the study. CAOV3

and OVCAR3 cells were purchased from American Type Culture Collection (ATCC, Manassas,

VA), cultured in Dulbecco's modified Eagles media (Hyclone), 5% fetal bovine serum

(BioAbChem, Ladson, SC), 4%Insulin-Transferrin-Selenium (Gibco, USA)), 100 U/ml penicillin

and 100 U/ml streptomycin (Hyclone), 2 mM L-glutamine, and 1 mM sodium pyruvate. F2 cells

transduced to express mCherry (mCherry-F2) [34, 35] were developed and kindly provided by

Dr. Gil Mor (Wayne State University, Detroit, MI). These cells were cultured in Roswell Park

Memorial Institute base medium, 10% fetal bovine serum, 1% penicillin-streptomycin, 1%

HEPES, 1% minimum essential media with non-essential amino acids NEAA and 1% sodium

pyruvate. All cells were cultured at 37ºC in a humidified 5% CO_2 incubator. CPI-613

(Devimistat) was obtained from Cornerstone Pharmaceuticals (Cranbury, NJ).

Animal model and experiments

Induction of intra-peritoneal ovarian cancer. Female nude mice of 6-8 weeks were acquired

from Jackson Laboratory (Bar Harbor, ME) and were maintained under standard optimized

conditions in the animal facility at Henry Ford Hospital (Detroit, MI). Prior to the start of the

study, mice were acclimated in house for 1 week. To induce ovarian cancer, mice were injected

intraperitoneally (IP) with 5 x 10^6 OVCAR3, F2 and CAOV3 cells in 200 ul of phosphate-

buffered saline. Body weight and tumor growth were monitored once a week till the end of the

study as previously reported [36]. Mice were sacrificed when the abdominal circumference

reached 8 cm or when they exhibited partial impaired mobility.

Induction of subcutaneous ovarian cancer. Female nude mice of 6-7 weeks age obtained from

Jackson Laboratory were acclimatized for 1-2 weeks. To induce subcutaneous tumors, 2×10^6

cells/200 µl F2 cells were injected subcutaneously into the left flank of each mouse. When

tumors grew an average volume of 100 mm^3, mice were randomly grouped into control (vehicle

corn oil) or CPI-613, chemotherapy and chemotherapy and CPI-613 combination. Tumor volume

was calculated as described previously [37].

Treatments. All treatments were started after 1 week of tumor injection. All CPI-613 mice were

injected with 2.5 mg/kg body weight in corn oil for 4 weeks post-tumor injections for 3 days in a

week. For chemotherapy mice received 20 mg/kg body weight of carboplatin and 50 mg/kg of

paclitaxel for 6 cycles, 2 doses a week for 3 weeks.

Survival curve. For estimating overall survival, 7 or 9 mice per group were injected with

respective cells and tumors were allowed to proceed until the abdominal circumference reached

8 cm for IP tumors. For the subcutaneous model, mice were euthanized when the tumors reached

a size of 1000 mm^3, according to the Henry Ford Health Institutional Animal Care and Use

Committee approved end point. The mice were then humanely euthanized. Survival curves were

generated using Kaplan-Meir analysis using Prism 10 (GraphPad Software, La Jolla, CA).

In situ fluorescence imaging of tumors. The mCherry fluorescence signals of the tumor were

recorded using the Xenogen IVIS system 2000 series (Perkin Elmer, Akron, OH). Images were

acquired over a period of 20 minutes with a 15-second exposure. Living Image software (Perkin

Elmer) was used to read and integrate the total fluorescence signals in each region. Fluorescence

measurements were quantified as total photon flux emission as photons/second in the images

acquired at the same exposure time for the various groups [38].

Ethics statement

All protocols were approved by the Henry Ford Hospital Institutional Animal Care and Use

Committee prior to any experiments (#1472). All institutional and national guidelines for the care

and use of laboratory animals were followed.

Alamar blue viability assay

CAOV3, F2 and OVCAR3 cells (2000 cells/well) were cultured in the presence and absence of

various doses of CPI-613 ranging from 5 to 250 µm. After 72 hours of incubation at 37°C and

5% CO_2, Alamar blue was added to the cultures according to the manufacturer's protocol

(BioRad, Hercules, CA). After incubation for 4 hours, absorbance was measured using a

SYNERGY H1 Hybrid reader. For estimating growth of various fuels, cells were plated in

Dulbecco's Modified Eagle Media containing high pyruvate (1 mM) or low pyruvate (0.1 mM)

and high (2.5 mM) or low glutamine (0.5 mM). Alamar blue assay was performed at 0-72 hours

of respective media exposure. The test was run in triplicate and repeated thrice. The results were

expressed as percentage of cell viability.

Seahorse metabolic analysis

OVCAR3, CaOV3 and F2 cells or single cell suspension of tumor cells isolated from CaoV3 and

F2 xenografts were plated at a density of 7×10^4 cells/well in cell-Tak coated XFe 96 cell plates.

Oxygen consumption rate (OCR) and extracellular acidification (ECAR) rate were measured

using XFe 96 seahorse bioanalyzer (Agilent Seahorse XF Analyzers, Santa Clara, CA) and

analyzed as describe before [16, 36, 38, 39].

Real-time polymerase chain reaction

RNA extraction was performed as described previously [39-41]. In brief, RNA was extracted

from cultured cells or tumors of control and CPI-613 treated mice using an RNA assay kit

(Qiagen, Germantown, MD) and quantified by Qubit Fluorimeter (Thermo Fisher Scientific,

Waltham, MA). The cDNA was synthesized using 1 µg of total RNA using high quantity cDNA

kit in 20 µl reaction mixture using CFX BioRad Real-time PCR (polymerase chain reaction)

Detection System. Ribosomal protein L27 was used as a housekeeping gene. All the primers

were purchased from Integrated DNA Technologies (Coralville, IA) and Real time Primers

(Melrose Park, PA). All primers used in the study are detailed in the supplementary material

(Table S1).

Western blotting

Western blotting was performed as published before [36, 38]. In brief, after indicated treatments,

the total protein was isolated from tumor cells after lysing cells in a protein lysis buffer (50 mM

Tris-HCl, pH 7.5, 250 mM NaCl, 5 mM EDTA, 50 mM NaF, and 0.5% Nonidet P-40; containing

a protease inhibitor cocktail; Sigma-Aldrich, St Louis, MO), and quantified using BCA

(Bicinchononic acid assay kit; Thermo Fisher). An equal amount of protein was separated by 4-

20% sodium dodecyl sulphate polyacrylamide gel electrophoresis and transferred onto the

polyvinylidene difluoride membrane and blocked with 5% skimmed milk. Antibodies used

included anti-DLST, PDHa, cytochrome C, apoptotic protease activating factor 1 (APAF1),

cleaved caspase 3, cleaved caspase 9, cleaved PARP and β-actin. All antibodies were purchased

from Cell Signaling Technologies (Danvers, MA) and were diluted at a ratio of 1:1000 in 5%

BSA for primary antibody incubation.

Immunohistochemistry

Tumor tissue was fixed in 10% formaldehyde for 48 hours and paraffin embedded. Sections were

cut and processed for immunohistochemistry to detect Ki-67. The Ki-67 antibody was purchased

from Abcam (Cambridge, MA) and used at a concentration of 1:200. Solutions obtained from

Dako Cytomation (Carpinteria, CA) were used for performing immunostaining, using the Dako

Autostainer Link 48 as described previously [38]. A minimum of 3-6 slides per group and 6-10

fields per slide were evaluated under a high-power field using Nikon eclipse Ci-S microscope

(Melville, NY).

Quantitation of TCA metabolites by LC-MS/MS

The levels of TCA metabolites in tumor cells of untreated, CPI-613, chemotherapy and

chemotherapy and CPI-613 combination mice were quantified by ultrahigh performance liquid

chromatography-tandem mass spectroscopy (LC-MS/MS) (Waters, Milford, MA) as described

before [37, 42]. *Chemicals and reagents.* TCA cycle standard mix 1 and 2 (cat no. MSK-TCA1

and MSK-TCA 2A) and its ^{13}C-labeled metabolites were purchased from Cambridge Isotope

Laboratories, Inc. (Tewksbury, MA). Acetonitrile (HPLC-grade), formic acid, MS-grade water

and methanol were purchased from Sigma-Aldrich.

TCA metabolites LC-MS method for extraction and quantification. As per experimental design,

all the metabolites were extracted using 80:20 acetonitrile and water mixture. TCA standards

were reconstituted in (water and acetonitrile, 20:80) to prepare 10 mg/ml stock solutions. Linear

standards curve at the range of 5-1000 ng/ml of each analyte (citric acid, aconitase, iso-citric

acid, α-ketoglutaric acid, itaconate, α-ketoglutarate, succinic acid, fumarate, and malic acid) was

produced from stock solutions in the relevant matrix. Each standard (100 μl) was mixed to

obtain a 7-point standard calibration curve within a range of 5-1000 ng/ml. Each internal

standard (10 μg/ml) (isotope-labelled TCA mixtures standards mix Sets 1 and 2A) were spiked

into all samples as an internal standard (final concentration) to allow quantification based on the

ratio of the internal standard to each intermediate peak. Approximately, 3 million cells were

rapidly rinsed by 2 mL of 37°C deionized water to the cell surface. Cells were collected in 2-ml

tubes after washing, followed by adding 500 µL of extraction solution (acetonitrile and water

[80:20]) and stored at -80°C for further processing. 10 µL of each isotope-labeled TCA mixtures

standards mix (Sets 1 and 2A) was added as an internal standard followed by vortex to mix.

Three cycles of extraction were carried out by vertexing for 1 minute followed by sonicating for

1 minute (each). After sonication, samples were kept at -20°C for protein precipitation, followed

by centrifugation at 15,000 rpm for 20 minutes at 4°C. Supernatants were loaded into pre-

conditioned Phenomenex Strata XL-100 60 mg/3 ml cartridges (Torrance, CA) and passed

through it using positive pressure manifold (Agilent Technologies). Flow through was collected

subsequently and 100 µL of filtrate was mixed with 100 µL of water for the LC-MS/MS system.

The TCA cycle and its intermediate metabolites were identified and quantified based on

retention time and m/z match to injections of authentic standards, retention time and accuracy

bases and were quantified using internal standard area for the respective metabolites.

Phenomenex Luna-NH2, 2.0 x 150 mm, 3 µm column was used to achieve an optimal separation

of all TCA intermediates. The flow rate of 0.25 ml/min was used with a mobile phase A (10 mM

NH_4OAc buffer at pH 9.8) and mobile phase B (acetonitrile). Column temperature was

optimized at 25°C for the best chromatographic separation. The metabolites were eluted from the

column at a flow rate of 0.25 ml/min using a gradient system (mobile phase B): 80% (0.01–0.5

min), 80→20% (0.5–18.0 min), 20% (18.0–19.5 min), 20 → 80% (19.5–22 min), and re-

equilibration (22–25 minutes). TCA cycle intermediates were monitored using negative MRM

(multi reaction monitoring) polarity. Identification was achieved based on retention time and

MS/MS ion conformation. Seven calibration standards ranging from 5-1000 ng/ml were

subjected to the full extraction procedure 3 times before analysis. The mean correlation

coefficients of each metabolite were linear r2 > 0.99 and were obtained (n = 3) from 5-1000

ng/ml. The calibration curve, prepared in a control matrix, was constructed using peak area ratios

of the calibration samples by applying a one/concentration weighting (1/x) linear regression

model. All quality control sample concentrations were then calculated from their PARs against

the calibration curve. The parameters for triple quadrupole detector mass spectrometry equipped

with an electrospray ionization probe: Capillary, voltage, 3.5 kV for negative mode: Source

temperature 120°C :Desolvation temp: 450°C; Cone gas flow: 150 L/h: Desolvation gas

flow:1000 L/Hr Collision gas flow: 0.25 mL/min and nebulizer gas flow: 7 Bar.

Data analysis. Mass spectrometric data was acquired by MassLynx v4.2software (Waters,

Milford, MA. TargetLynx software was used for preparing the calibration curve and absolute

quantitation of all TCA metabolites in the samples. Analyte concentrations were calculated using

a 1/x weighted linear regression analysis of the standard curve.

Mitochondrial dysfunction detection

Mitochondrial membrane potential. Single cell suspension of the xenografts was prepared using

Accutase (Innovative Cell Technologies, San Diego, CA). Tumor cells were labeled with Ep-

CAM (APC/Cyanine7 anti-mouse CD326 Antibody, BioLegend, San Diego, CA) for

identification. MitoProbe TMRM (tetramethylrhodamine methyl ester) kit for flow cytometry

(Invitrogen, # M20036) was used as per manufacturer's instructions to measure the membrane

potential. Attune NXT flow cytometer (Thermo Fisher Scientific, Waltham, MA) set to excite

and emit light at 488/575 nm was used for measurements.

Mitochondrial superoxide detection. Single cell suspension of the xenografts was prepared using

Accutase (Innovative Cell Technologies). Tumor cells were labeled with Ep-CAM as above for

identification and treated with MitoSOX red dye (Thermo Fisher) for 15 minutes, washed 3

times, and then analyzed using an Attune NXT flow cytometer with excitation and emission

wavelengths of about 396/610 nm. For microscopic detection, cells were treated with CPI-613 at

a concentration of 100 µM for 48 hours. Subsequently, 5 µM of the fluorogenic dye MitoSOX

Red was applied to the cells on coverslips to measure mitochondrial superoxide levels, and the

cells were incubated for 15 minutes. The cells were then washed and counterstained with DAPI

(4′,6-diamidino-2-phenylindole) for imaging. Intensity of MitoSOX positive cells were measured

using Nikon NIS Imaging software (Melville, NY).

Measurement of lipid peroxidation. Lipid peroxidation was measured by detection of

malondialdehyde in the tumor lysates using Lipid Peroxidation kit (AbCaM, #ab118970) as per

the manufacturer's instructions.

Mitochondrial metabolism array. A human mitochondrial energy metabolism PCR array (Qiagen

RT2 Profiler PCR Arrays, PAHS-008YA) was performed from cDNA synthesized from 1 µg of

total RNA from the tumors of control and CPI-613 treated mice. This library profiles 84 genes

involved in mitochondrial energy metabolism. The quantitative expression of the gene was

calculated from the cycle threshold value of each sample and was normalized using the

housekeeping genes by using online PCR quantification software provided by the manufacturer

[43].

Statistical analysis

An unpaired t-test or one-way analysis of variance was used where appropriate. Kaplan Meier

analysis was used to determine the survival curve. The significance of survival curves was

estimated by using the Gehan Breslow-Wilcox test and the Mantel-Cox tests. All analyses were

carried out using Prism 10 (GraphPad Software, La Jolla, CA).

Results

Chemoresistant ovarian cancer cells are dependent on OXPHOS

We have previously shown that chemoresistant ovarian cancer cells are metabolically energetic

with increased OXPHOS [16]. To confirm our previous observations, we performed carboplatin

sensitivity and bioenergetic profiling of chemosensitive (OVCAR3) and chemoresistant (F2 and

CAOV3) cell lines. F2 and CAOV3 exhibited resistance to carboplatin (Fig. 1A), an increased

oxygen consumption rate with differential ECAR compared to chemosensitive OVCAR3 (Fig.

1B-E), confirming our previous observations [16] of chemoresistance correlating with increased

OXPHOS and a highly metabolically active phenotype (Fig. 1F). Next, we compared the

dependency of sensitive and resistant cell lines on pyruvate and glutamine, the two major fuels

for maintaining an upregulated TCA cycle [44, 45]. Sensitive OVCAR3 cells showed no effect

on growth when glutamine was reduced and when pyruvate was reduced in media, minimal

growth inhibition was seen, indicating that if glucose is present as a carbon source, these can

survive and grow (Fig. 1G and 1J). In contrast, both resistant cell lines F2 and CaOV3 showed

reduced proliferation under low glutamine or pyruvate conditions (Fig. 1H, 1I, 1K, and 1L),

despite glucose being present in the media. Interestingly growth was more dependent on

glutamine compared to pyruvate in both F2 and CaOV3 cell lines (Fig. 1K and 1L). This

indicates that the increased TCA cycle is being sustained both by pyruvate and glutamine,

especially glutamine. Further, we assessed the expression of key enzymes PDHc and αKGDC

that facilitate the entry of pyruvate and glutamine into the TCA cycle respectively. Both F2 and

CaOV3 cells showed increased mRNA expression of DLST (dihydrolipoamide S-

succinyltransferase), the E2 transferase subunit of αKGDC [46] and PDH subunits; PDH1a and

PDH1b [47] compared to OVCAR3 (Fig. 1M-O). Higher expression of DLST and PDH1a was

further validated at the protein level in the resistant cell lines (Fig 1P-R). Thus, chemoresistant

metabolically active ovarian cancer cells upregulate the 2 key nodes of TCA cycle to maintain a

high OXPHOS via upregulation of TCA cycle.

CPI-613 inhibits growth and improves overall survival in ovarian cancer xenografts

Because of the increased TCA cycle, OXPHOS and dependency on pyruvate and glutamine, we

selected CPI-613, an inhibitor of the TCA cycle that inhibits the 2 key nodes of TCA cycle:

PDHc and αKGDC [18, 21, 24]. We evaluated the efficacy of CPI-613 in the sensitive OVCAR3

and resistant F2 and CAOV3 IP xenografts as detailed in the Methods section. Overall survival

was significantly improved in all 3 models by CPI-613 as seen by an increase in survival by 11

days in OVCAR3, 12 days in CAOV3 and most profoundly by 18 days in F2 bearing xenograft

mice, the most resistant and aggressive cell line (Fig. 2A, 2C, and 2E). The increase in survival

was supported by the reduction in tumor weights (Fig. 2B, 2D, and 2F). Histological analysis of

the Ki-67 stained tumor tissue indicated CPI-613 significantly reduced the number of

proliferating tumor cells compared to vehicle treated xenografts in all 3 models (Fig. 2G-L).

Thus, CPI-613 is effective in inhibiting both chemotherapy sensitive and resistant ovarian

tumors.

CPI-613 inhibits TCA cycle in ovarian cancer xenografts

To validate that CPI-613 can inhibit the TCA cycle and modulates the energy metabolism of the

xenografts, we determined the level of TCA cycle enzymes and mitochondrial activity in CPI-

613 treated xenografts. CPI-613 treated tumors from OVCAR3, CaOV3 and F2 xenografts

showed a significant decrease in the mRNA expression of its target enzymes; αKGDC subunits:

DLST, DLD (dihydrolipoamide dehydrogenase), and OGDH (oxoglutarate dehydrogenase) and

both the PDHc subunits: PDH1a and PDH1b (Fig 3A-C). This was also confirmed by decreased

protein expression of DLST and PDH1a in the tumors treated with CPI-613 (Fig. 3D-G).

Bioenergetic analysis by Seahorse bioanalyzer of the single cell suspensions of the

extracted tumors showed that CPI-613 completely suppressed basal and stressed oxygen

consumption rate, compared to vehicle treated tumors, indicating a collapse of energy production

by the mitochondria (Fig. 3H-J). No significant change was seen in the ECAR at the baseline or

stressed conditions, suggesting that glycolysis was not impacted by CPI-613 (Fig. S1). To further

confirm that TCA cycle is impacted by CPI-613, we quantified key TCA metabolites by LC-

MS/MS-based analysis [37, 42]. While the levels of key metabolites detected varied between the

tumors, there was consistent decrease in levels of αKG (alpha-ketoglutarate) and succinic acid in

all 3 tumors, indicating a strong suppression of αKGDC and entry of glutamine into the TCA

cycle (Fig. 3K-M). Citrate levels were not altered between control and CPI-613 treated F2 and

OVCAR3 tumors, while CAOV3 tumors in the CPI-613 group had increased citric acid levels,

suggesting a variable impact on PDHc and pyruvate entry into the TCA cycle (Fig. 3K-M) or

presence of an alternate fuel source. Fumarate and malate levels were also significantly increased

in CPI-613 treated OVCAR3, CAOV3 and F2 tumors, suggesting synthesis of key metabolites

even if the αKG to succinate step is blocked via alternate pathways. Thus, CPI-613 inhibits TCA

cycle/mitochondrial respiration and modulates energy metabolism in both sensitive and resistant

ovarian tumors.

CPI-613 restores chemosensitivity in chemoresistant ovarian xenografts. To determine if CPI-

613 can specifically enhance chemotherapy efficacy in the chemoresistant ovarian tumors, we

tested the combination of CPI-613 and chemotherapy in the chemoresistant CaOV3 and

mCherry-F2 IP xenograft models. Chemotherapy alone improved survival by only 6 days in the

CaOV3 xenografts, while a combination of chemotherapy and CPI-613 resulted in a more than

20-day increase with a profound decrease observed in the tumor weights (Fig S2). In mCherry-

F2 IP model, chemotherapy alone improved survival by only 4 days in contrast to CPI-613,

while the combination with CPI-613, survival was improved by approximately 30 days (Fig.

4A). The survival improvements were reflected in the tumor burden as assessed by final tumor

end weights (Fig 4B) and in situ imaging of mCherry in the F2 tumors at 5 weeks post-tumor

injections (Fig 4C and 4D). To further test the efficacy of the combination treatment,

subcutaneous F2 xenografts were allowed to grow to a volume of approximate $100mm^3$, prior to

randomizing and starting treatments. While chemotherapy alone showed minimal abatement in

the tumor growth, both CPI-613 alone and CPI-613 and chemotherapy combination groups

showed a significant decrease in tumor growth (Fig. 4E) and tumor weight (Fig. 4F). This

translated to an enhanced overall survival of the combination group (Fig. 4G), when compared to

chemotherapy alone group, as well as CPI-613 alone group. Survival in the combination group

was improved by 31 days compared to chemotherapy alone and by 14 days compared to CPI-613

alone (Fig 4G). The impressive inhibition in tumor growth was mirrored in the in-situ imaging of

the mCherry in the F2 tumors at 5-weeks post-therapy (Fig 4H and I). Thus, CPI-613 alone is

effective against aggressive chemoresistant ovarian tumors and can also enhance the efficacy of

chemotherapy against chemoresistant ovarian tumors.

CPI-613 reverses the chemotherapy induced metabolic reprogramming in chemoresistant

ovarian xenografts. We and others have previously demonstrated that platinum chemotherapy

can induce mitochondrial respiration, a highly active metabolic phenotype and is associated with

development of chemotherapy resistance [16, 48, 49]. Seahorse bioanalyzer profiling of the fresh

single cell suspension of the xenografts isolated from F2 and CaOV3 treated tumors showed that

chemotherapy treated tumors had increased OCR in both models (Fig 5A, B, F, and G), while

ECAR was increased in F2 tumors (Fig S3). CPI-613 effectively inhibited the chemotherapy

induced bioenergetic increases of both OCR (Fig 5A, B, F, G) and ECAR (Fig S3), indicating its

ability to reverse the chemotherapy induced bioenergetic adaptations in ovarian tumors.

Measurement of the TCA cycle metabolites showed that chemotherapy did not affect the key

downstream metabolites of αKDGC; αKG and succinate in both CaOV3 (Fig 5D and 5E) and F2

(Fig 5I and 5J) tumors. Similarly, acetyl coenzyme A (acetyl-CoA), the downstream metabolite

of PDHc, was not impacted by chemotherapy but surprisingly increased by CPI-613 in both

tumor models (Fig 5C and 5H), indicating a source other than pyruvate contributing to acetyl-

CoA synthesis as a compensatory mechanism [50]. Overall, CPI-613 can inhibit chemotherapy

induced mitochondrial respiration and TCA cycle reprograming.

CPI-613 causes mitochondrial collapse in chemoresistant ovarian xenografts

Since we observed a drastic decrease in OXPHOS in response to CPI-613, we postulated that

CPI-613 may be causing a complete mitochondrial collapse. Single cell suspension from

xenografts were measured for mitochondrial dysfunction. We first measured the mitochondrial

membrane potential as it represents the electrochemical gradient between the interior and

exterior of the mitochondria and is a sign of healthy mitochondria and cells [16, 51]. Ep-CAM

positive tumor cells from CPI-613 treated CaOV3 and F2 xenografts showed significant decrease

in TMRE florescence indicating mitochondrial membrane depolarization (Fig. 6A-C and 6E-G),

which was further supported by decreased ATP levels (Fig 6D and 6H). Another marker of

mitochondrial dysfunction is the generation of superoxide, a toxic product that results in

accumulated oxidative damage indicated by lipid peroxides or modified DNA bases [52, 53].

Using MitoSox red mitochondrial superoxide indicator, we observed an increase in the

fluorescent dye in Ep-CAM positive tumor cells from CPI-613 treated CaOV3 and F2

xenografts, indicating the presence of increased oxidation products (Fig. 6I-L). This was further

supported by an increased lipid peroxidation as seen by increased levels of malondialdehyde

(MDA)[53], in both xenografts (Fig. 6M and 6N). Microscopic analysis of the ovarian cancer

cells stained by MitoSox also validated the increased fluorescence and presence of superoxide in

response to CPI-613 (Fig 6O-R). Using mRNA isolated from CPI-613 treated and untreated

xenografts, we performed a mitochondrial metabolism PCR array that measured 84 genes crucial

for mitochondria metabolism and respiration. We observed that in CPI-613 treated xenografts,

majority of the gene expression was downregulated compared to control CaOV3 and F2 tumors

(Fig S4). Interestingly, while many similar mitochondrial genes were inhibited in both the

xenograft models, the extent of gene expression inhibition between the 2 xenografts was differed

(Fig S4).

Mitochondrial damage can induce apoptosis by release of pro-apoptotic proteins into the

cytoplasm, resulting in mitochondrial mediated apoptosis [54]. CPI-613 treated xenografts

showed increased apoptosome proteins [55]: cytochrome C, APAF1 and caspase 9 (Fig. 6S-U),

in contrast to untreated control xenografts. The apoptosome formation in response to CPI-613

resulted in final activation of caspase 3 and cell death as observed by an increase in expression of

cleaved caspase 3 and PARP (Fig. 6S-U), indicating apoptosis in both F2 and CAOV3 tumors.

Thus CPI-613 has the potential to induce mitochondria collapse and the ensuing mitochondrial

mediated apoptosis in chemoresistant ovarian tumors.

Discussion

Ever since metabolic reprogramming was identified as a characteristic of cancer, the importance of mitochondrial metabolism in driving tumor development, tumor metastasis, chemotherapy resistance, and radiation resistance has taken center stage [56]. Previous studies, including our own, have shown that abnormal mitochondria, specifically an overactive TCA cycle, play a significant role in providing metabolic advantages to ovarian cancer cells [14-16]. This metabolic advantage promotes aggressive growth, helps the cells evade therapy, and maintains their CSC-like behavior. These findings suggest that targeting mitochondrial function could be a potential strategy for inhibiting ovarian cancer.

In our current study, we provide evidence of the substantial effectiveness of CPI-613, a lipoate analog that inhibits both PDHc and αKGDC of the TCA cycle, in combating chemoresistant ovarian cancer xenografts. Our initial findings confirmed our previous observation that the chemoresistant ovarian cancer cell lines CaOV3 and F2 are metabolically active, utilizing both glycolysis and higher OXPHOS [16]. This metabolic activity is associated with their reliance on TCA fuels, specifically pyruvate and glutamine, even in the presence of glucose. Additionally, these cell lines showed increased expression of PDHc and αKGDC subunits, in contrast to the chemosensitive OVCAR3 cell line. CPI-613 effectively suppressed the growth of OVCAR3, CaOV3, and F2 xenografts, leading to enhanced overall survival. Notably, it had the most pronounced impact on the F2 cell line, which is characterized by higher aggressiveness and resistance to chemotherapy. Significantly, CPI-613 enhanced the effectiveness of chemotherapy in both the xenografts that were resistant to treatment. The data indicate that CPI-613 has potential as an anti-tumor agent, particularly against chemoresistant ovarian cancer. A recent study showcased the efficacy of CPI-613 in specifically targeting

CSCs derived from the ovarian cancer cell lines and xenografts [20]. It also exhibited the

potential of CPI-613 to limit the enrichment of CSCs caused by chemotherapy and PARPi. CSCs

in ovarian and other malignancies are responsible for the development of recurrent and

chemoresistant disease [34, 48]. Multiple studies have demonstrated that CSCs rely on metabolic

flexibility for their survival and prefer OXPHOS [34, 48]. A recent publication, which has not

undergone peer review, provides evidence of the efficacy of CPI-613 in specifically targeting

pancreatic cancer CSCs[57]. Therefore, our finding that the CSC enriched F2 cell is highly

affected by CPI-613 aligns with these reports. Nevertheless, we observe a suppression of tumor

growth in the xenografts, irrespective of CSCs, leading to an enhancement in survival rates.

Preclinical studies in several types of tumors have verified that the primary mechanism of

CPI-613 is the inhibition of PDHc and αKGDC, resulting in the inhibition of the TCA cycle,

which affects mitochondrial activity and leads to the death of tumor cells. CPI-613 has the ability

to alter lipid metabolism in pancreatic cancer, which triggers AMPK-ACC signaling [23]. This

signaling pathway ultimately leads to apoptosis and autophagy [23]. In colorectal cancer, CPI-

613 causes cell cycle arrest and apoptosis mediated by Bcl2-like protein 11, Bim [27]. Both

investigations also indicated a reduction in mitochondrial activity and the production of reactive

oxygen species [23]. Our study also confirms the inhibition of PDHc and αKGDC leading to

TCA cycle inhibition and decreased mitochondrial respiration.

Interesting observations were seen when TCA metabolites were measured in xenografts

in response to CPI-613. The most consistent was the almost absence of αKG and succinate,

indicating a significant impact of CPI-613 on αKGDC inhibition, which would block conversion

of αKG to succinyl-CoA leading to succinate [50]. The decrease in αKG suggests that CPI-613 is

also able to block glutamine-glutamate-αKG analplerosis [58] into the TCA cycle, but we did not

observe any change in the levels of glutamate in the tumor cell (Fig. S5). Alternately, it may

indicate an increase in reductive carboxylation of αKG to citrate [58], as citrate levels were

unchanged in OVCAR3 and F2 but increased in CaOV3 tumors. The increase in this metabolic

route is supported by the increase seen in other metabolites like itaconate from isocitrate [56] and

an unexpected increase in acetyl-CoA (Fig. S5) in CaOV3 and F2 tumors, which was predicted

to decreased in response to PDHc inhibition by CPI-613. An increase in acetyl CoA may also

reflect the compensatory increase in use of fatty acid reserves [50, 58] by the cancer cells to

maintain the TCA cycle for survival. While itaconate is a well-known anti-inflammatory and

immunomodulator metabolite [25], its role in tumor biology is controversial [59, 60]. On the

other hand, acetyl-CoA has been shown to mainly promote tumor growth due to its multiple

functions as fuel and transcriptional regulation by chromatin remodeling [61]. Another

interesting metabolite change observed was an increase in fumarate, primarily considered an

oncometabolite [62], despite the block in succinate synthesis. These data indicate that the

intricate overlapping metabolic routes come into play on inhibition of the TCA cycle by CPI-

613, perhaps as an attempt to maintain the energy metabolism and survival of the cancer cells.

These observations also exhibit the diverse response of each cell type/xenograft in response to

the metabolic inhibitor CPI-613, underlining the existence of heterogeneity.

Nevertheless, the significant reduction in OXPHOS and the severe decrease of key TCA

cycle metabolites observed in both chemoresistant ovarian tumor cells and those treated with

chemotherapy and/or CPI-613, indicates a substantial decline in mitochondrial activity. We

verified this by identifying reduction in mitochondrial membrane potential, accompanied by a

fall in ATP levels. Additionally, we saw an increase in mitochondrial superoxide production,

which correlated with lipid peroxidation. Furthermore, there was a decrease in the expression of

almost all genes associated with mitochondrial energy and metabolism. This indicates a total

breakdown of mitochondria, which resulted in apoptosis. Our observations confirm the induction

of the mitochondrial mediated apoptotic cascade, as evidenced by the increase in apoptosome

levels and the activation of caspase 3, leading to PARP cleavage.

Conclusions

Our work shows that CPI-613 has a significant effect on the TCA cycle and mitochondrial

function, ultimately resulting in the death of tumor cells. CPI-613 exhibits a discerning effect on

chemoresistant cancer cells, likely because these cells and CSCs rely more heavily on OXPHOS.

Although the recent performance of CPI-613 in clinical trials has been disappointing, recent post

hoc analysis of trials indicate that select patient populations may be able to benefit from CPI-

613. A post-hoc analysis of the acute myeloid leukemia clinical trial indicates a trend of dose

response in older patients in contrast to younger patients [33]. This is pertinent to ovarian cancer

as it primarily effects elderly women and for whom age constitutes a substantial risk factor [1,

63]. Therefore, CPI-613 exhibits considerable promise as a pharmaceutical candidate deserving

of additional investigations, whether utilized in isolation or in conjunction with conventional

chemotherapy or targeted therapies, particularly in the case of chemoresistant ovarian cancer.

Declarations

Availability of data and materials: Not applicable. No datasets were generated during this

work.

Competing interests: The authors declare that they have no competing interests.

Funding: This work was supported by HFH-Game on Cancer funding to RR.

Authors' contributions: M.P.U., H.S., T. B., K.A. and S.P., performed research, analyzed the

data, and edited the manuscript; F.R. performed research and analyzed the data; T.P., S. L.,

M.H., R.G., P.P., A.M. and S.G. participated in data discussions and designing the study and

edited the manuscript; R.R. designed and supervised research, analyzed the data and edited the

manuscript.

Acknowledgements: We would like to thank Cornerstone Pharmaceuticals for providing us

CPI-613. We would like to thank Ms. Stephanie Stebens for editing and formatting the

manuscript.

List of Abbreviations

αKDGC: alpha-ketoglutarate dehydrogenase complex
αKG: alpha-ketoglutarate
ACC: acetyl-CoA carboxylase
AMPK: AMP-activated protein kinase
APAF1: apoptotic protease activating factor 1
ATP: adenosine triphosphate
DNA: deoxyribonucleic Acid
BSA: bovine serum albumin
CoA: Coenzyme A
CSC: cancer stem cells
CD: cluster of differentiation
DAPI: 4′,6-diamidino-2-phenylindole
DLD: dihydrolipoamide dehydrogenase
DLST: dihydrolipoamide S-succinyltransferase
ECAR: extracellular acidification
EDTA: ethylenediamine tetraacetic acid
Ep-CAM: epithelial cell adhesion molecule
HCl: hydrochloric acid
LC/MS/MS: liquid chromatography tandem mass spectrometry
MDA: malondialdehyde
NaCl: sodium chloride
NaF: sodium fluoride
OCR: oxygen consumption rate
OGDH: oxoglutarate dehydrogenase
OXPHOS: oxidative phosphorylation
PARP: poly-ADP ribose polymerase

PARPi: poly-ADP ribose polymerase inhibitors
PDHc: pyruvate dehydrogenase complex
TCA: tricarboxylic acid
TMRM: tetramethylrhodamine methyl ester
548
549

References

1.   Siegel RL, Miller KD, Wagle NS, Jemal A: **Cancer statistics, 2023**. *CA Cancer J Clin*

2023, **73**(1):17-48.

2.   Konstantinopoulos PA, Matulonis UA: **Clinical and translational advances in ovarian**

cancer therapy. *Nat Cancer* 2023, **4**(9):1239-1257.

3.   Kim S, Han Y, Kim SI, Kim HS, Kim SJ, Song YS: **Tumor evolution and**

chemoresistance in ovarian cancer. *NPJ Precis Oncol* 2018, **2**:20.

4.   Li X, Ng ASN, Mak VCY, Chan KKL, Cheung ANY, Cheung LWT: **Strategic**

Combination Therapies for Ovarian Cancer. *Curr Cancer Drug Targets* 2020,

20(8):573-585.

5.   Tendulkar S, Dodamani S: **Chemoresistance in Ovarian Cancer: Prospects for New**

Drugs. *Anticancer Agents Med Chem* 2021, **21**(6):668-678.

6.   Hirschey MD, DeBerardinis RJ, Diehl AME, Drew JE, Frezza C, Green MF, Jones LW,

Ko YH, Le A, Lea MA *et al*: **Dysregulated metabolism contributes to oncogenesis**.

Semin Cancer Biol 2015, **35**(Suppl):S129-S150.

7.   DeBerardinis RJ, Chandel NS: **Fundamentals of cancer metabolism**. *Sci Adv* 2016,

2(5):e1600200.

8.   Pavlova NN, Zhu J, Thompson CB: **The hallmarks of cancer metabolism: Still**

emerging. *Cell Metab* 2022, **34**(3):355-377.

9.   Nayak AP, Kapur A, Barroilhet L, Patankar MS: **Oxidative phosphorylation: a target**

for novel therapeutic strategies against ovarian cancer. *Cancers (Basel)* 2018,

10(9):337.

10. Ma L, Zong X: **Metabolic Symbiosis in Chemoresistance: Refocusing the Role of**

Aerobic Glycolysis. *Front Oncol* 2020, **10**:5.

11. Sato M, Kawana K, Adachi K, Fujimoto A, Yoshida M, Nakamura H, Nishida H, Inoue

T, Taguchi A, Takahashi J *et al*: **Spheroid cancer stem cells display reprogrammed**

metabolism and obtain energy by actively running the tricarboxylic acid (TCA)

cycle. *Oncotarget* 2016, **7**(22):33297-33305.

12. Ding Y, Labitzky V, Legler K, Qi M, Schumacher U, Schmalfeldt B, Sturken C,

Oliveira-Ferrer L: **Molecular characteristics and tumorigenicity of ascites-derived**

tumor cells: mitochondrial oxidative phosphorylation as a novel therapy target in

ovarian cancer. *Mol Oncol* 2021, **15**(12):3578-3595.

13. Pendleton KE, Wang K, Echeverria GV: **Rewiring of mitochondrial metabolism in**

therapy-resistant cancers: permanent and plastic adaptations. *Front Cell Dev Biol*

2023, **11**:1254313.

14. Hu B, Guo Y: **Inhibition of mitochondrial translation as a therapeutic strategy for**

human ovarian cancer to overcome chemoresistance. *Biochem Biophys Res Commun*

2019, **509**(2):373-378.

15. Pasto A, Bellio C, Pilotto G, Ciminale V, Silic-Benussi M, Guzzo G, Rasola A, Frasson

C, Nardo G, Zulato E *et al*: **Cancer stem cells from epithelial ovarian cancer patients**

privilege oxidative phosphorylation, and resist glucose deprivation. *Oncotarget* 2014,

5(12):4305-4319.

16.   Dar S, Chhina J, Mert I, Chitale D, Buekers T, Kaur H, Giri S, Munkarah A, Rattan R:

594   **Bioenergetic Adaptations in Chemoresistant Ovarian Cancer Cells**. *Sci Rep* 2017,

595   **7**(1):8760.

596   17.   Ashton TM, McKenna WG, Kunz-Schughart LA, Higgins GS: **Oxidative**

597   **Phosphorylation as an Emerging Target in Cancer Therapy**. *Clin Cancer Res* 2018,

598   **24**(11):2482-2490.

599   18.   Neitzel C, Demuth P, Wittmann S, Fahrer J: **Targeting altered energy metabolism in**

600   **colorectal cancer: oncogenic reprogramming, the central role of the TCA cycle and**

601   **therapeutic opportunities**. *Cancers (Basel)* 2020, **12**(7):1731.

602   19.   Pardee TS, Lee K, Luddy J, Maturo C, Rodriguez R, Isom S, Miller LD, Stadelman KM,

603   Levitan D, Hurd D *et al*: **A phase I study of the first-in-class antimitochondrial**

604   **metabolism agent, CPI-613, in patients with advanced hematologic malignancies**.

605   *Clin Cancer Res* 2014, **20**(20):5255-5264.

606   20.   Bellio C, DiGloria C, Spriggs DR, Foster R, Growdon WB, Rueda BR: **The metabolic**

607   **inhibitor CPI-613 negates treatment enrichment of ovarian cancer stem cells**.

608   *Cancers (Basel)* 2019, **11**(11):1678.

609   21.   Kumstel S, Schreiber T, Goldstein L, Stenzel J, Lindner T, Joksch M, Zhang X, Wendt

610   EHU, Schönrogge M, Krause B *et al*: **Targeting pancreatic cancer with combinatorial**

611   **treatment of CPI-613 and inhibitors of lactate metabolism**. *PLoS One* 2022,

612   **17**(4):e0266601.

613   22.   Zachar Z, Marecek J, Maturo C, Gupta S, Stuart SD, Howell K, Schauble A, Lem J,

614   Piramzadian A, Karnik S *et al*: **Non-redox-active lipoate derivates disrupt cancer cell**

mitochondrial metabolism and are potent anticancer agents in vivo. *J Mol Med*

(Berl) 2011, **89**(11):1137-1148.

23.   Gao L, Xu Z, Huang Z, Tang Y, Yang D, Huang J, He L, Liu M, Chen Z, Teng Y: **CPI-**

613 rewires lipid metabolism to enhance pancreatic cancer apoptosis via the AMPK-

ACC signaling. *J Exp Clin Cancer Res* 2020, **39**(1):73.

24.   Khan HY, Kamgar M, Aboukameel A, Bannoura S, Chung BY, Li Y, Hallak MNA,

Philip PA, Tsai S, Luther S *et al*: **Targeting Cellular Metabolism With CPI-613**

Sensitizes Pancreatic Cancer Cells to Radiation Therapy. *Adv Radiat Oncol* 2023,

8(1):101122.

25.   Lang L, Wang F, Ding Z, Zhao X, Loveless R, Xie J, Shay C, Qiu P, Ke Y, Saba NF *et*

al: **Blockade of glutamine-dependent cell survival augments antitumor efficacy of**

CPI-613 in head and neck cancer. *J Exp Clin Cancer Res* 2021, **40**(1):393.

26.   Egawa Y, Saigo C, Kito Y, Moriki T, Takeuchi T: **Therapeutic potential of CPI-613**

for targeting tumorous mitochondrial energy metabolism and inhibiting autophagy

in clear cell sarcoma. *PLoS One* 2018, **13**(6):e0198940.

27.   Arnold C, Demuth P, Seiwert N, Wittmann S, Boengler K, Rasenberger B, Christmann

M, Huber M, Brunner T, Linnebacher M *et al*: **The Mitochondrial Disruptor**

Devimistat (CPI-613) Synergizes with Genotoxic Anticancer Drugs in Colorectal

Cancer Therapy in a Bim-Dependent Manner. *Mol Cancer Ther* 2022, **21**(1):100-112.

28.   Alistar A, Morris BB, Desnoyer R, Klepin HD, Hosseinzadeh K, Clark C, Cameron A,

Leyendecker J, D'Agostino R, Jr., Topaloglu U *et al*: **Safety and tolerability of the first-**

in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with

metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1

trial. *Lancet Oncol* 2017, **18**(6):770-778.

29.   Pardee TS, Luther S, Buyse M, Powell BL, Cortes J: **Devimistat in combination with**

high dose cytarabine and mitoxantrone compared with high dose cytarabine and

mitoxantrone in older patients with relapsed/refractory acute myeloid leukemia:

ARMADA 2000 Phase III study. *Future Oncol* 2019, **15**(28):3197-3208.

30.   Philip PA, Buyse ME, Alistar AT, Rocha Lima CM, Luther S, Pardee TS, Van Cutsem E:

A Phase III open-label trial to evaluate efficacy and safety of CPI-613 plus modified

FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic

adenocarcinoma of the pancreas. *Future Oncol* 2019, **15**(28):3189-3196.

31.   Mangieri CW, Valenzuela CD, Solsky IB, Erali RA, Pardee T, Lima C, Howerton R,

Clark CJ, Shen P: **Comparison of survival for metastatic pancreatic cancer patients**

treated with CPI-613 versus resected borderline-resectable pancreatic cancer

patients. *J Surg Oncol* 2023, **128**(5):844-850.

32.   Philip PA, Bahary N, Mahipal A, Kasi A, Lima CMSPR, Alistar AT, Oberstein PE,

Golan T, Sahai V, Metges JP *et al*: **Phase 3, multicenter, randomized study of CPI-613**

with modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) as first-line

therapy for patients with metastatic adenocarcinoma of the pancreas

(AVENGER500) [abstract]. *J Clin Oncol* 2022, **40**(16 Suppl):4023.

33.   Anderson R, Miller LD, Isom S, Chou JW, Pladna KM, Schramm NJ, Ellis LR, Howard

DS, Bhave RR, Manuel M *et al*: **Phase II trial of cytarabine and mitoxantrone with**

devimistat in acute myeloid leukemia. *Nat Commun* 2022, **13**(1):1673.

34.   Craveiro V, Yang-Hartwich Y, Holmberg JC, Joo WD, Sumi NJ, Pizzonia J, Griffin B,

660   Gill SK, Silasi DA, Azodi M *et al*: **Phenotypic modifications in ovarian cancer stem**

661   **cells following Paclitaxel treatment**. *Cancer Med* 2013, **2**(6):751-762.

662   35.   Alvero AB, Fox A, Madina BR, Krady MM, Gogoi R, Chehade H, Nakaar V, Almassian

663   B, Yarovinsky TO, Rutherford T *et al*: **Immune Modulation of Innate and Adaptive**

664   **Responses Restores Immune Surveillance and Establishes Antitumor Immunologic**

665   **Memory**. *Cancer Immunol Res* 2024, **12**(2):261-274.

666   36.   Udumula MP, Poisson LM, Dutta I, Tiwari N, Kim S, Chinna-Shankar J, Allo G, Sakr S,

667   Hijaz M, Munkarah AR *et al*: **Divergent metabolic effects of metformin merge to**

668   **enhance eicosapentaenoic acid metabolism and inhibit ovarian cancer in vivo**.

669   *Cancers (Basel)* 2022, **14**(6):1504.

670   37.   Udumula MP, Singh H, Faraz R, Poisson L, Tiwari N, Dimitrova I, Hijaz M, Gogoi R,

671   Swenor M, Munkarah A *et al*: **Intermittent Fasting induced ketogenesis inhibits**

672   **mouse epithelial ovarian tumors by promoting anti-tumor T cell response**. *bioRxiv*

673   2023:10:2023.2003.2008.531740.

674   38.   Udumula MP, Sakr S, Dar S, Alvero AB, Ali-Fehmi R, Abdulfatah E, Li J, Jiang J, Tang

675   A, Buekers T *et al*: **Ovarian cancer modulates the immunosuppressive function of**

676   **CD11b(+)Gr1(+) myeloid cells via glutamine metabolism**. *Mol Metab* 2021,

677   **53**:101272.

678   39.   Udumula MP, Singh H, Rashid F, Poisson L, Tiwari N, Dimitrova I, Hijaz M, Gogoi R,

679   Swenor M, Munkarah A *et al*: **Intermittent fasting induced ketogenesis inhibits mouse**

680   **epithelial ovarian cancer by promoting antitumor T cell response**. *iScience* 2023,

681   **26**(10):107839.

40. Udumula MP, Mangali S, Kalra J, Dasari D, Goyal S, Krishna V, Bollareddy SR, Sriram

D, Dhar A, Bhat A: **High fructose and streptozotocin induced diabetic impairments**

are mitigated by Indirubin-3-hydrazone via downregulation of PKR pathway in

Wistar rats. *Sci Rep* 2021, **11**(1):12924.

41. Kalra J, Mangali SB, Bhat A, Dhar I, Udumula MP, Dhar A: **Imoxin attenuates high**

fructose-induced oxidative stress and apoptosis in renal epithelial cells via

downregulation of protein kinase R pathway. *Fundam Clin Pharmacol* 2018,

32(3):297-305.

42. Suhail H, Nematullah M, Rashid F, Sajad M, Fatma M, Singh J, Zahoor I, Cheung WL,

Tiwari N, Ayasolla K *et al*: **An early glycolysis burst in microglia regulates**

mitochondrial dysfunction in oligodendrocytes under neuroinflammation. *iScience*

2023, **26**(10):107921.

43. Barton GP, Sepe JJ, McKiernan SH, Aiken JM, Diffee GM: **Mitochondrial and**

Metabolic Gene Expression in the Aged Rat Heart. *Front Physiol* 2016, **7**:352.

44. Yang C, Ko B, Hensley CT, Jiang L, Wasti AT, Kim J, Sudderth J, Calvaruso MA,

Lumata L, Mitsche M *et al*: **Glutamine oxidation maintains the TCA cycle and cell**

survival during impaired mitochondrial pyruvate transport. *Mol Cell* 2014,

56(3):414-424.

45. Anderson NM, Mucka P, Kern JG, Feng H: **The emerging role and targetability of the**

TCA cycle in cancer metabolism. *Protein Cell* 2018, **9**(2):216-237.

46. Ali G, Wasco W, Cai X, Szabo P, Sheu KF, Cooper AJ, Gaston SM, Gusella JF, Tanzi

RE, Blass JP: **Isolation, characterization, and mapping of gene encoding**

dihydrolipoyl succinyltransferase (E2k) of human alpha-ketoglutarate

dehydrogenase complex. *Somat Cell Mol Genet* 1994, **20**(2):99-105.

47.　DeBrosse SD, Kerr DS: **Pyruvate dehydrogenase complex deficiency in**

mitochondrial case studies. In: *Mitochondrial case studies: underlying mechanisms and*

diagnosis. edn. Edited by Saneto RP, Parikh S, Cohen BH. Boston: Academic Press

2016: 93-101.

48.　Sriramkumar S, Sood R, Huntington TD, Ghobashi AH, Vuong TT, Metcalfe TX, Wang

W, Nephew KP, O'Hagan HM: **Platinum-induced mitochondrial OXPHOS**

contributes to cancer stem cell enrichment in ovarian cancer. *J Transl Med* 2022,

20(1):246.

49.　Koc ZC, Sollars VE, Bou Zgheib N, Rankin GO, Koc EC: **Evaluation of mitochondrial**

biogenesis and ROS generation in high-grade serous ovarian cancer. *Front Oncol*

2023, **13**:1129352.

50.　Salway JG: **Regulation of Krebs cycle**. In: *Metabolism at a glance.* 3rd edn. Edited by

Noyes V. Malden, MA: Blackwell Publishing; 2004: 56-57.

51.　Zorova LD, Popkov VA, Plotnikov EY, Silachev DN, Pevzner IB, Jankauskas SS,

Babenko VA, Zorov SD, Balakireva AV, Juhaszova M *et al*: **Mitochondrial membrane**

potential. *Anal Biochem* 2018, **552**:50-59.

52.　Dingley S, Chapman KA, Falk MJ: **Fluorescence-activated cell sorting analysis of**

mitochondrial content, membrane potential, and matrix oxidant burden in human

lymphoblastoid cell lines. *Methods Mol Biol* 2012, **837**:231-239.

53.   Brand MD, Affourtit C, Esteves TC, Green K, Lambert AJ, Miwa S, Pakay JL, Parker N:

726   **Mitochondrial superoxide: production, biological effects, and activation of**

727   **uncoupling proteins**. *Free Radic Biol Med* 2004, **37**(6):755-767.

728   54.   Green DR, Kroemer G: **The pathophysiology of mitochondrial cell death**. *Science*

729   2004, **305**(5684):626-629.

730   55.   Ai Y, Meng Y, Yan B, Zhou Q, Wang X: **The biochemical pathways of apoptotic,**

731   **necroptotic, pyroptotic, and ferroptotic cell death**. *Mol Cell* 2024, **84**(1):170-179.

732   56.   Martinez-Reyes I, Chandel NS: **Mitochondrial TCA cycle metabolites control**

733   **physiology and disease**. *Nat Commun* 2020, **11**(1):102.

734   57.   Li1 Z, Xie1 B, Wu2 P, Wang1 J, Liu2 H, Dong1 Z, Huang1 L: **CPI-613 Suppresses**

735   **Pancreatic Cancer Stem-Like Cells by Targeting the SEMA3A/NRP1 Pathway**.

736   *Research Square* 2024, **PREPRINT (Version 1)** (15 January 2024).

737   58.   Owen OE, Kalhan SC, Hanson RW: **The key role of anaplerosis and cataplerosis for**

738   **citric acid cycle function**. *J Biol Chem* 2002, **277**(34):30409-30412.

739   59.   Wang HC, Chang WC, Lee DY, Li XG, Hung MC: **IRG1/Itaconate induces metabolic**

740   **reprogramming to suppress ER-positive breast cancer cell growth**. *Am J Cancer Res*

741   2023, **13**(3):1067-1081.

742   60.   Gu X, Wei H, Suo C, Shen S, Zhu C, Chen L, Yan K, Li Z, Bian Z, Zhang P *et al*:

743   **Itaconate promotes hepatocellular carcinoma progression by epigenetic induction of**

744   **CD8(+) T-cell exhaustion**. *Nat Commun* 2023, **14**(1):8154.

745   61.   Guertin DA, Wellen KE: **Acetyl-CoA metabolism in cancer**. *Nat Rev Cancer* 2023,

746   **23**(3):156-172.

747 62. Valcarcel-Jimenez L, Frezza C: **Fumarate hydratase (FH) and cancer: a paradigm of**

748 **oncometabolism**. *Br J Cancer* 2023, **129**(10):1546-1557.

749 63. Tew WP: **Ovarian cancer in the older woman**. *J Geriatr Oncol* 2016, **7**(5):354-361.

 Figure Legends

 Figure 1: Chemoresistant ovarian cancer cells are dependent on oxidative phosphorylation.

(A) OVCAR3, Caov3 and F2 cells (2000 cells/well in triplicates) were plated in 96 well plates

and treated with indicated concentrations of CPI-613 and 72 hours later, cell viability was

assessed using the Alamar blue viability assay. (B) OVCAR3, Caov3 and F2 cells (70,000

cells/well in triplicates) were subjected to real-time XFe Seahorse analysis for bioenergetics

profiling. Oxygen consumption rate (OCR) an indicator for mitochondrial respiration was

assessed with port injections of (1) oligomycin, (2) FCCP (Carbonyl cyanide-p-

trifluoromethoxyphenylhydrazone), and a combination of (3) rotenone-antimycin. (D)

Extracellular acidification rate (ECAR), an indicator of glycolysis, was measured with port

injections of (1) glucose, (2) oligomycin, and (3) 2-DG (2-deoxyglucose). (C, E) The bar graph

represents basal and stressed OCR and ECAR (n=3). (F) The ratio of basal OCR and ECAR was

plotted to ascertain the metabolic phenotype of the cells as per XFe Seahorse analysis. (G, H, I)

OVCAR3, CaOV3 and F2 cells (2000 cells/well in triplicates) were plated in 96 well plates and

subjected to growth conditions of media containing high pyruvate (1 mM) or low pyruvate (0.1

mM) and high (2.5 mM) or low glutamine (0.5 mM). Cell viability was examined by Alamar

blue assay at 0-72 hours of respective media exposure. The test was repeated thrice. (J, K, L) The

bar graph represents the final cell viability at 72 hours of various media exposure. (M, N, O)

mRNA isolated from all 3 cell lines were subjected to Qpcr to measure the expression levels of

(M) DLST; dihydrolipoamide S-succinyltransferase (N) PDH1a; pyruvate dehydrogenase E1

subunit alpha 1 and (O) PDHb; pyruvate dehydrogenase E1 subunit beta. (P) Representative

immunoblots showing expression of DLST, PDH1a and beta-actin. (Q, R) Bar plots show

normalized densitometry analysis from 2 individual blots.

Figure 2: CPI-613 inhibits growth and improves overall survival in ovarian cancer

xenografts. (A) OVCAR3, (C) CaOV3 and (E) F2 intraperitoneal xenografts (n=8) were treated

with 2.5 mg/kg body weight of CPI-613 thrice a week in corn oil and observed for survival as

described in the Methods section. Control groups were treated with corn oil alone. The

significance of the Kaplan Meier graph was estimated by Gehan-Breslow-Wilcoxon test. MS =

median survival in days. Bar graph shows average tumor weights isolated from the (B)

OVCAR3, (D) CaOV3 and (F) F2 mouse models (n=8). Representative immunohistochemistry

images (400x) showing Ki67 stain in (G) OVCAR3, (H) CaOV3 and (I) F2 xenografts. (J, K, L)

Bar graphs show the Ki-index calculated from $n = 5$ images per group at high-power field (HPF).

Figure 3: CPI-613 inhibits TCA cycle in ovarian cancer xenografts. Pooled tumor tissue

(n=4) was used to isolate mRNA from (A) OVCAR3, (B) CaOV3 and (C) F2 xenografts and

subjected to quantitative polymerase chain reaction to estimate the expression levels of

dihydrolipoamide dehydrogenase (DLD), oxoglutarate dehydrogenase (OGDH),

dihydrolipoamide S-succinyltransferase (DLST), pyruvate dehydrogenase E1 subunit alpha 1

(PDH1a) and pyruvate dehydrogenase E1 subunit beta (PDHb). (D) Representative immunoblots

showing expression of DLST, PDH1a and beta-actin in proteins isolated from 3 individual

mouse tumor tissue of OVCAR3, CaOV3 and F2 xenografts. (E, F, G). Bar plots show

normalized densitometry analysis from 2 individual blots from each cell line. (H-J) Single cell

suspension was prepared from freshly isolated xenografts (n=3), cells were pooled to plate

70,000 cells/well in triplicates and subjected to real-time XFe Seahorse analysis for bioenergetics

profiling. Oxygen consumption rate (OCR), an indicator for mitochondrial respiration, was

assessed with port injections of (1) oligomycin, (2) FCCP (Carbonyl cyanide-p-

trifluoromethoxyphenylhydrazone), and a combination of (3) rotenone-antimycin in xenografts

from (H) OVCAR3, (I) CaOV3 and (J) F2. The bar graph represents basal and stressed OCR. (K-

M) Targeted analysis of the TCA cycle metabolites was performed to assess the levels of various

metabolites in pooled xenografts (n=3) in triplicates from (K) OVCAR3, (L) CaOV3 and (M)

F2. The schematic figure represents a simplified version of the TCA cycle.

Figure 4: CPI-613 restores chemosensitivity in chemoresistant ovarian xenografts. (A)

mCherry-F2 intraperitoneal xenografts (n=8) were treated with CPI-613 alone, chemotherapy

(Chemo) alone and a combination of both (CPI-613 + Chemo) and observed for survival as

described in the Methods section. The significance of the Kaplan Meier graph was estimated by

Gehan-Breslow-Wilcoxon test. (B) Bar graph showing isolated average tumor weights. (C)

Representative mCherry bioluminescence pictures indicative of tumor burden. (D) Quantification

of the fluorescence signals was done by measuring total photon flux emission/second at the same

exposure time for the various groups. mCherry-F2 subcutaneous xenografts (n=7) were allowed

to grow to an average size of 100 mm^3 before treating with CPI-613 alone, chemotherapy

(Chemo) alone and a combination of both (CPI-613 + Chemo). (E) Trajectory of tumor growth

as represented by measurement of tumor volume. (F) Bar graph showing isolated average tumor

weights at the end of the study. (G) Kaplan Meier graph representing the survival of mice. The

significance of the Kaplan Meier graph was estimated by Gehan-Breslow-Wilcoxon test. (H)

Quantification of the fluorescence signals was done by measuring total photon flux

emission/second at the same exposure time for the various groups shown as representative

mCherry bioluminescence pictures indicative of tumor burden (I).

Figure 5: CPI-613 reverses the chemotherapy induced metabolic reprogramming in

chemoresistant ovarian xenografts. Single cell suspension was prepared from freshly isolated

(A) CaOV3 and (F) F2 xenografts (n=3), cells were pooled to plate 70,000 cells/well in

triplicates and subjected to real-time XFe Seahorse analysis for bioenergetics profiling. Oxygen

consumption rate (OCR), an indicator for mitochondrial respiration, was assessed with port

injections of (1) oligomycin, (2) FCCP, and a combination of (3) rotenone-antimycin. (B, G) The

bar graph represents basal and stressed OCR. Targeted analysis of the TCA cycle metabolites

was performed to assess the levels of various metabolites in pooled xenografts (n=3) in

triplicates. Key metabolites are shown as (C, H) acetyl CoA, (D, I) alpha- ketoglutarate (αKG),

and (E, J) succinate.

Figure 6: CPI-613 causes mitochondrial collapse in chemoresistant ovarian xenografts. (A

& E) Single cell suspensions were prepared from freshly isolated xenografts (n=3), cells were

pooled and cells in triplicates were labeled with epithelial cell marker Ep-CAM antibody and

Mitoprobe TMRM (tetramethylrhodamine methyl ester) and mitochondria membrane potential

was measured using flow cytometry. Representative flow cytometry pictures of Ep-CAM

positive cells displaying TMRM fluorescence in (A) CaOV3 and (E) F2 xenografts. (B, F)

Representative histograms showing the shift of polarization in cells from both xenografts. (C, G)

Quantification of the Ep-CAM positive cells with TMRM measured by flow cytometry. ATP

levels were measured as per manufacturer's instructions in single cell suspensions from (D)

CaOV3 and (H) F2 xenografts. Mitosox Red was used to measure the mitochondria superoxide

in single cell suspensions from (I, J) CaOV3 and (K, L) F2 xenografts in Ep-CAM positive cells

by flow cytometry. Bar graphs represent the quantification of the Mitosox Red signal. Lipid

peroxidation was measured by measuring the malondialdehyde (MDA) in single cell suspensions

from (M) CaOV3 and (N) F2 xenografts by ELISA. Caov3 cells (O) and (Q) F2 cells were plated

on coverslips and treated with CPI-613 (100 μM) for 48 hours and then stained with Mitosox

Red and counterstained with DAPI. Representative fluorescence images are shown (400x

magnification). (P, R) Bar graphs show quantification of the fluorescence intensity measured in

400x objective field from 3 slides per treatment. (S) Representative immunoblots showing

expression of cytochrome C, APAF1 (apoptotic protease activating factor-1), cleaved caspase 3

(cleaved C3), cleaved caspase 9 (cleaved C9), cleaved PARP and beta-actin in proteins isolated

from 3 individual mouse tumor tissue of CaOV3 and F2 xenografts. (E, F, G) Bar plots show

normalized densitometry analysis from 2 individual blots from each cell lines. (T, U) Bar plots

show normalized densitometry analysis from 2 individual blots from each xenograft.

Figure 1: Chemoresistant ovarian cancer cells are dependent on oxidative phosphorylation

Figure 2: CPI-613 inhibits growth and improves survival in ovarian cancer xenografts.

Figure 3: CPI-613 inhibits TCA cycle in ovarian xenografts.

Figure 4: CPI-613 retsores chemosensitivity in chemoresistant ovarian xenografts.

Figure 5: CPI-613 reverses the chemotherapy induced metabolic reprogramming.

Figure 6: CPI-613 causes mitochondrial collapse and apoptosis in chemoresistant xenografts.